1. Circ Cardiovasc Interv
Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer
by Masahiro Natsuaki, Ken Kozuma, Takeshi Morimoto, Kazushige Kadota, Toshiya Muramatsu, Yoshihisa Nakagawa, Takashi Akasaka, Keiichi Igarashi, Kengo Tanabe, Yoshihiro Morino, Tetsuya Ishikawa, Hideo Nishikawa, Masaki Awata, Mitsuru Abe, Hisayuki Okada, Yoshiki Takatsu, Nobuhiko Ogata, Kazuo Kimura, Kazushi Urasawa, Yasuhiro Tarutani, Nobuo Shiode, and Takeshi Kimura
Circ Cardiovasc Interv
Volume 8(10):e002817
October 7, 2015
Copyright © American Heart Association, Inc. All rights reserved.

2. Study patient flow.
Study patient flow. BP-BES indicates biodegradable polymer biolimus-eluting stent; and DP-EES, durable polymer everolimus-eluting stent.
Masahiro Natsuaki et al. Circ Cardiovasc Interv. 2015;8:e002817
Copyright © American Heart Association, Inc. All rights reserved.

3. Cumulative incidence of persistent discontinuation of dual antiplatelet therapy.
Cumulative incidence of persistent discontinuation of dual antiplatelet therapy. BP-BES indicates biodegradable polymer biolimus-eluting stent; DP-EES, durable polymer everolimus-eluting stent; and PCI, percutaneous coronary intervention.
Masahiro Natsuaki et al. Circ Cardiovasc Interv. 2015;8:e002817
Copyright © American Heart Association, Inc. All rights reserved.

4. Cumulative incidences of the primary safety and efficacy end point events through 3-year follow-up; (A) death or myocardial infarction, and (B) target-lesion revascularization.
Cumulative incidences of the primary safety and efficacy end point events through 3-year follow-up; (A) death or myocardial infarction, and (B) target-lesion revascularization. BP-BES indicates biodegradable polymer biolimus-eluting stent; DP-EES, durable polymer everolimus-eluting stent; and PCI, percutaneous coronary intervention.
Masahiro Natsuaki et al. Circ Cardiovasc Interv. 2015;8:e002817
Copyright © American Heart Association, Inc. All rights reserved.

5. Cumulative incidences of the safety and efficacy end point events between 1 and 3 years by the 1-year landmark analysis; (A) death or myocardial infarction, and (B) target-lesion revascularization.
Cumulative incidences of the safety and efficacy end point events between 1 and 3 years by the 1-year landmark analysis; (A) death or myocardial infarction, and (B) target-lesion revascularization. BP-BES indicates biodegradable polymer biolimus-eluting stent; DP-EES, durable polymer everolimus-eluting stent; and PCI, percutaneous coronary intervention.
Masahiro Natsuaki et al. Circ Cardiovasc Interv. 2015;8:e002817
Copyright © American Heart Association, Inc. All rights reserved.

6. HR plot for the safety end point of death/MI in the prespecified subgroups.
HR plot for the safety end point of death/MI in the prespecified subgroups. BP-BES indicates biodegradable polymer biolimus-eluting stent; CI, confidence interval; DM, diabetes mellitus; DP-EES, durable polymer everolimus-eluting stent; HR, hazard ratio; MI, myocardial infarction; and PCI, percutaneous coronary intervention.
Masahiro Natsuaki et al. Circ Cardiovasc Interv. 2015;8:e002817
Copyright © American Heart Association, Inc. All rights reserved.